Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine

Altimmune (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced additional positive data from a Phase 2a study of its NasoVAX intranasal influenza vaccine candidate.

As quoted in the press release:

An influenza specific mucosal antibody (IgA) response was demonstrated at all dose levels of NasoVAX, with the highest responses in the highest dose groups, while Fluzone and placebo groups demonstrated no response.  Mucosal antibodies can be found in tears, saliva and nasal mucous and are a first line of immune defense thereby preventing influenza infection at the site of entry in the respiratory tract.

Serum antibody levels for NasoVAX were very stable through at least six months (the last time point tested), unlike Fluzone where antibody levels declined by over 50% during that time period.  Flu season typically runs from October through March in the northern hemisphere according to the Centers for Disease Control (CDC), but most individuals are vaccinated very early in the Fall.  The fact that NasoVAX induced antibodies that were very stable over the six month follow up period may indicate a higher likelihood of protection throughout the entire flu season.

 Click here to read the full press release.